The clinical study results of ‘PNEUMOSTEM®’ the premature baby chronic pulmonary disease treatment drug which is being jointly researched by MEDIPOST and Samsung Seoul Hospital has been published in international academic journal.
MEDIPOST announced that Professors Wonsoon Park and Yoonsil Jang of Pediatric Department, Samsung Seoul Hospital, Medical School of Seongkyunkwan University successfully carried out Phase 1 clinical study of premature baby chronic pulmonary disease treatment drug ‘PNEUMOSTEM®’ and that the results were published in international pediatric journal ‘The Journal of Pediatrics’.
Premature baby chronic pulmonary disease is the most important causal disease of death and complications in premature babies with no special treatment method until now, however joint research of industrial and academics between Korean medical circle and pharmaceutical companies allowed one more step towards development of a new treatment drug.
In this clinical study, the research team proved the safety and efficacy of ‘PNEUMOSTEM®’ targeting 9 super premature babies of 24-26 weeks into pregnancy when there is very high risk of premature baby chronic pulmonary disease.
In particular, while the occurrence of severe premature baby chronic pulmonary disease remained at 72% in existing high risk group premature babies, it decreased to less than half being 33% in the ‘PNEUMOSTEM®’ treatment group, confirming treatment efficacy and possibility.
Research personnel for this research stated that ‘there is great meaning in the fact that research on premature baby chronic pulmonary disease without existing special treatment method has been done in Korea, succeeding in clinical study for the first time in the world with medicine made in Korea.
‘PNEUMOSTEM®’ used in this clinical study is a premature baby chronic pulmonary disease treatment made from mesenchymal stem cells extracted from cord blood (blood from umbilical cord), with phase 1 Korean clinical study successfully finished and phase 2 clinical study in progress.
